Pharmacokinetic and exposure –response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer

ConclusionsPertuzumab exposure in JACOB was consistent with prior studies in advanced gastric cancer and breast cancer. The 840  mg q3w dose allowed the majority of patients in JACOB to achieve target pertuzumab concentrations and appears to be an appropriate dose selection.

Source: Cancer Chemotherapy and Pharmacology - June 9, 2019 Category: Cancer & Oncology Source Type: research